Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Capecitabine and Temozolomide for Neuroendocrine Cancers
NCT00869050Phase 2Completed
- Sponsor
- Columbia University
- Start
- Aug 2005
- Primary completion
- Dec 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and temozolomide in neuroendocrine tumors (NETs), sponsored by Columbia University. Primary endpoints: Number of Participants With Partial Response (PR) at 12 months and Number of Participants With Complete Response (CR) at 12 months. Started Aug 2005; status: completed.
02
Drugs
capecitabinetemozolomide
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT00869050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00869050.